Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Actelion highlights revenue growth in first quarter of 2011

Actelion highlights revenue growth in first quarter of 2011

27th April 2011

Actelion has published its financial report for the first quarter of 2011, during which the company was able to achieve year-on-year revenue growth.

The firm's total net revenue figure for the three months came to 528.2 million Swiss francs (364.51 million pounds), representing an increase of 15 percent in local currency terms, despite global pressures on healthcare spending.

Actelion's managing director and chief executive officer Jean-Paul Clozel attributed this performance to the strength of its pulmonary arterial hypertension franchise, which is a key area of focus for the company.

He also highlighted the fact that new clinical study data will be published for key developmental compounds such as macitentan and Selexipag in the coming months, which will assist in the development of its longer-term strategy.

"The data on these compounds will also allow us to evaluate potential partnering opportunities as part of our strategy to maximise shareholder value while at the same time managing our overall portfolio risk," Mr Clozel explained.

Earlier this month, the company was presented with the European Institute for Creative Strategies and Innovation's Prix Hermes de l'Innovation, thanks to its work in researching cures for rare diseases affecting children.ADNFCR-8000103-ID-800512680-ADNFCR

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.